LA Improves the Prognosis of Patients With ICVD
Launched by HUAQIU ZHANG · Apr 26, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a specific probiotic, Lactobacillus acidophilus, might help improve cognitive function in patients with ischemic cerebrovascular disease, which is a condition that affects blood flow to the brain and can lead to serious health issues. Researchers believe that this probiotic could positively affect the brain by influencing the gut, a connection often referred to as the "brain-gut axis."
To be eligible for the trial, participants need to be between 35 and 65 years old, of Han nationality, and have mild to moderate symptoms of ischemic cerebrovascular disease. They should also be able to communicate well and complete certain tests on their own. It's important that participants have not had any major surgeries, previous strokes, or a history of severe mental health issues. If someone joins the trial, they will receive a drink containing the probiotic and be monitored for improvements in their cognitive abilities over time. Additionally, the trial is not yet recruiting, so interested individuals will need to wait for it to start.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Between 35 and 65 years old;
- • 2. Han nationality;
- • 3. Diagnosed as ischemic cerebrovascular disease with mild to moderate symptoms;
- • 4. Can communicate normally, complete neuropsychological tests independently, and sign informed consent;
- • 5. No previous surgical history;
- • 6. No contraindications such as PET, MRI and DSA;
- • 7. No history of stroke identified by imaging;
- • 8. No family history of other chronic diseases, cancer, mental illness or dementia;
- • 9. Improved Rankin scale score ≤2;
- • 10. Ischemic symptoms appeared in the carotid area ≤3 months before the visit;
- • 11. In line with the surgical treatment of ischemic cerebrovascular disease;
- Exclusion Criteria:
- • 1. previous dementia;
- • 2. hearing or visual impairment;
- • 3. Drugs that may or are known to influence cognitive abuse;
- • 4. alcohol addiction;
- • 5. Diagnosis of depression, schizophrenia and other psychiatric diseases;
- • 6. MRI showed severe cerebral infarction;
- • 7. Those allergic to Lactobacillus acidophilus;
- • 8. Baseline CT showed intracranial hemorrhage;
- • 9. ischemic onset accompanied by epilepsy;
- • 10. illiteracy;
- • 11. pregnancy or breastfeeding;
- • 12. any serious medical condition that may interact with treatment;
About Huaqiu Zhang
Huaqiu Zhang is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and robust methodologies. With a strong focus on collaboration, Huaqiu Zhang leverages extensive expertise in clinical development to facilitate the efficient execution of trials across various therapeutic areas. The sponsor prioritizes ethical conduct, regulatory compliance, and the integration of patient perspectives, ensuring that all research initiatives contribute meaningfully to the scientific community and address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported